Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04070846 · ClinicalTrials.gov registry record · Phase 1
Mass Balance Study of [14C]LC350189 in Healthy Volunteers
A Phase 1 study, sponsored by LG Chem.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT04070846: Completed Phase 1 study, sponsored by LG Chem.
NCT04070846 is a Phase 1 study that has completed, run by LG Chem. The registered enrollment target is 6 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04070846, a Phase 1 study, has completed, sponsored by LG Chem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, single-dose, mass balance study designed to evaluate the absorption, metabolism, and excretion of \[14C\] radiolabeled LC350189 after oral administration.
Primary Outcome
Radioactivity is measured by radiation dosimetry.
Interventions
- DRUG [14C] LC350189
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-02-26 |
| Est. Completion | 2020-03-07 |
| Phase | Phase 1 |
What the finished NCT04070846 record still lists
NCT04070846 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 1 intervention - of which [14C] LC350189 is the first listed.
NCT04070846 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04070846 about?
NCT04070846 is a clinical study titled "Mass Balance Study of [14C]LC350189 in Healthy Volunteers". This is a Phase 1, open-label, single-dose, mass balance study designed to evaluate the absorption, metabolism, and excretion of \[14C\] radiolabeled LC350189 after oral administration.
What is the current status of trial NCT04070846?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-02-26. Estimated completion is 2020-03-07.
What interventions are being tested in trial NCT04070846?
The interventions under investigation include: [14C] LC350189 (DRUG).
Who is sponsoring clinical trial NCT04070846?
This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04070846's enrollment target sits among peer trials
6 1974th of 2000 higher than 12 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI